Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Political Reporter Online.
Press releases published on May 2, 2025

301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 2.5.2025 KLO 9.00 301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 301 521 …

Aalberts N.V.: Aalberts reports first quarter 2025 results
Utrecht, 2 May 2025 Aalberts reports first quarter 2025 results In the first quarter Aalberts realised EUR 778.3 million revenue, which translates into 3.3% organic revenue decline compared to the first quarter of last year. We realised EUR 105.7 million …

ING completes share buyback and announces new programme of up to €2.0 billion
ING completes share buyback and announces new programme of up to €2.0 billion ING announced today that it has completed the share buyback programme announced on 31 October 2024. The total number of ordinary shares repurchased under the programme is 125,848 …

ING posts 1Q2025 net result of €1,455 million, with strong growth in customer balances and fee income
CEO statement “While the geopolitical and macroeconomic circumstances remain uncertain, we believe there is an opportunity for Europe to collectively drive competitiveness and resilience through simplification of regulations and investments in …

Equinor sells the Peregrino field for USD 3.5 billion
Equinor Brasil Energia Ltda., a subsidiary of Equinor (OSE: EQNR, NYSE: EQNR), has entered into agreements(1) with Brazilian company Prio Tigris Ltda., a subsidiary of PRIO SA (PRIO3.SA) for a sale of its 60% operated interest in the Peregrino field in …

Equinor selger Peregrino-feltet for 3,5 milliarder USD
Equinor Brasil Energia Ltda., et datterselskap av Equinor ASA (OSE:EQNR, NYSE: EQNR), har inngått avtaler(1) om salg av sin egenopererte eierandel på 60 prosent i Peregrino-feltet i Brasil med det brasilianske selskapet Prio Tigris Ltda. (PRIO3.SA). PRIO, …

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming …